NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
7 trialsNCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00059722 2016-08-24
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
Sanofi
Phase 2 Completed
NCT00034879 2013-01-04
Iressa Expanded Access Program (EAP)
AstraZeneca
Phase 3 Completed
NCT00238251 2012-06-05
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
Swiss Cancer Institute
Phase 2 Completed
NCT00344773 2010-06-29
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
AstraZeneca
Phase 2 Completed